drugset / Trial / NCT03207334
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML.
Timeline
- Start
- 2018-11
- Primary completion
- 2021-01
- Completion
- 2022-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midostaurin | Small molecule | 50 mg | Oral |
| Background | Cytarabine | Small molecule | 1 g | Intravenous |
| Background | Cytarabine | Small molecule | 3 g | Intravenous |